Acoramidis Cuts Mortality Almost 50% and Stabilizes Biomarkers Through 54 Months
BridgeBio’s ATTRibute-CM open-label extension showed acoramidis cut all-cause mortality by 44.7% and cardiovascular mortality by 49.3% through Month 54 (p<0.0001 for both). Treatment stabilized NT-proBNP levels and maintained KCCQ-OS heart failure quality-of-life scores with no new safety signals.
1. Long-Term Survival Benefit
BridgeBio reported that the ATTRibute-CM open-label extension demonstrated a 44.7% reduction in all-cause mortality and 49.3% reduction in cardiovascular mortality with continuous acoramidis through Month 54 (p<0.0001 for both), marking the largest risk reduction observed at this timepoint in ATTR-CM trials.
2. Biomarker and Quality of Life Maintenance
The trial showed that acoramidis mitigated the rise in NT-proBNP compared with delayed treatment and sustained Kansas City Cardiomyopathy Questionnaire overall summary scores through 54 months, indicating durable stabilization of cardiac biomarkers and heart failure–related quality of life.
3. Safety Profile and Regulatory Status
Acoramidis maintained a favorable long-term safety profile with no new concerns, mirroring adverse event rates similar to placebo, and remains approved by the FDA (as Attruby) and EMA (as BEYONTTRA) for treating wild-type and hereditary ATTR-CM in adults.